A scalable human iPSC-based neuromuscular disease model on suspended biobased elastomer nanofiber scaffolds.

CRISPR-Cas9 amyotrophic lateral sclerosis biobased elastomer nanofibers high content image analysis human induced pluripotent stem cells optogenetics scalable neuromuscular disease modelling

Journal

Biofabrication
ISSN: 1758-5090
Titre abrégé: Biofabrication
Pays: England
ID NLM: 101521964

Informations de publication

Date de publication:
05 09 2023
Historique:
received: 02 03 2023
accepted: 24 08 2023
medline: 6 9 2023
pubmed: 25 8 2023
entrez: 24 8 2023
Statut: epublish

Résumé

Many devastating neuromuscular diseases currently lack effective treatments. This is in part due to a lack of drug discovery platforms capable of assessing complex human neuromuscular disease phenotypes in a scalable manner. A major obstacle has been generating scaffolds to stabilise mature contractile myofibers in a multi-well assay format amenable to high content image (HCI) analysis. This study describes the development of a scalable human induced pluripotent stem cell (iPSC)-neuromuscular disease model, whereby suspended elastomer nanofibers support long-term stability, alignment, maturation, and repeated contractions of iPSC-myofibers, innervated by iPSC-motor neurons in 96-well assay plates. In this platform, optogenetic stimulation of the motor neurons elicits robust myofiber-contractions, providing a functional readout of neuromuscular transmission. Additionally, HCI analysis provides rapid and automated quantification of axonal outgrowth, myofiber morphology, and neuromuscular synapse number and morphology. By incorporating amyotrophic lateral sclerosis (ALS)-related TDP-43

Identifiants

pubmed: 37619554
doi: 10.1088/1758-5090/acf39e
pmc: PMC10478173
doi:

Substances chimiques

Elastomers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M009513/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N025865/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 108874/Z/15/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT098503
Pays : United Kingdom

Informations de copyright

Creative Commons Attribution license.

Références

Stem Cell Reports. 2015 Apr 14;4(4):561-8
pubmed: 25801509
Stem Cells Cloning. 2018 Nov 09;11:85-93
pubmed: 30519053
Sci Rep. 2020 Apr 24;10(1):6918
pubmed: 32332853
Elife. 2018 Feb 20;7:
pubmed: 29460776
Science. 2008 Mar 21;319(5870):1668-72
pubmed: 18309045
Nat Rev Dis Primers. 2017 Oct 20;3:17085
pubmed: 29052611
Exp Neurol. 2004 Feb;185(2):232-40
pubmed: 14736504
Cell Rep. 2018 Apr 17;23(3):899-908
pubmed: 29669293
Adv Biosyst. 2019 Jul;3(7):
pubmed: 31428672
Elife. 2019 May 14;8:
pubmed: 31084710
SLAS Discov. 2018 Sep;23(8):790-806
pubmed: 29498891
ACS Appl Mater Interfaces. 2020 Aug 5;12(31):34643-34657
pubmed: 32639712
Cell Motil Cytoskeleton. 2004 Jul;58(3):200-11
pubmed: 15146538
J Neurosci. 2004 Sep 8;24(36):7848-58
pubmed: 15356197
Clin Transl Sci. 2022 Aug;15(8):2010-2023
pubmed: 35649245
Sci Adv. 2016 Aug 03;2(8):e1501429
pubmed: 27493991
Nat Biotechnol. 2015 Feb;33(2):204-9
pubmed: 25580598
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:231-261
pubmed: 32004094
Neuron. 2014 Mar 5;81(5):1001-1008
pubmed: 24508385
Dev Biol. 1972 Jun;28(2):407-29
pubmed: 4338026
Muscle Nerve. 2008 Apr;37(4):438-47
pubmed: 18236465
Biomaterials. 2011 May;32(14):3575-83
pubmed: 21324402
Semin Neurol. 2016 Oct;36(5):409-418
pubmed: 27704495
Nat Rev Dis Primers. 2021 Feb 18;7(1):13
pubmed: 33602943
Brain Commun. 2021 Oct 26;3(4):fcab255
pubmed: 35350711
Sci Rep. 2020 Aug 11;10(1):13575
pubmed: 32782331
Bio Protoc. 2023 Mar 05;13(5):e4624
pubmed: 36908638
PLoS One. 2021 May 19;16(5):e0239242
pubmed: 34010323
Adv Mater. 2022 May;34(18):e2110441
pubmed: 35231133
Sci Adv. 2018 Oct 10;4(10):eaat5847
pubmed: 30324134
Brain. 2013 Aug;136(Pt 8):2359-68
pubmed: 23824486
Sci Adv. 2021 Sep 10;7(37):eabi8787
pubmed: 34516770

Auteurs

Aimee Cheesbrough (A)

Centre for Gene Therapy & Regenerative Medicine, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, United Kingdom.
Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, United Kingdom.
UCL Centre for Biomaterials in Surgical Reconstruction and Regeneration, Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom.

Peter Harley (P)

Centre for Gene Therapy & Regenerative Medicine, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, United Kingdom.
Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, United Kingdom.

Federica Riccio (F)

Centre for Gene Therapy & Regenerative Medicine, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, United Kingdom.
Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, United Kingdom.

Lei Wu (L)

UCL Centre for Biomaterials in Surgical Reconstruction and Regeneration, Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom.

Wenhui Song (W)

UCL Centre for Biomaterials in Surgical Reconstruction and Regeneration, Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom.

Ivo Lieberam (I)

Centre for Gene Therapy & Regenerative Medicine, Faculty of Life Sciences & Medicine, King's College London, London SE1 9RT, United Kingdom.
Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE1 1UL, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH